Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03205423 · ClinicalTrials.gov registry record · Phase 2
Medication Development for Opioid and Alcohol Abuse
A Phase 2 study, sponsored by New York State Psychiatric Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 17
- Enrollment target
NCT03205423 is a Phase 2 study that has completed, run by New York State Psychiatric Institute. The registered enrollment target is 17 participants.
The verdict
NCT03205423, a Phase 2 study, has completed, sponsored by New York State Psychiatric Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 17 participants
- Enrollment target
Study Summary
The present proposal will evaluate the ability of gabapentin maintenance to reduce the abuse liability of alcohol, oxycodone, and alcohol in combination with oxycodone in participants with both Opioid Use Disorder and Alcohol Use Disorder.
Interventions
- DRUG Gabapentin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2017-08-01 |
| Est. Completion | 2021-12-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03205423
The ClinicalTrials.gov registry entry for NCT03205423 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New York State Psychiatric Institute, which has 364 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Gabapentin is the first listed.
NCT03205423 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03205423 about?
NCT03205423 is a clinical study titled "Medication Development for Opioid and Alcohol Abuse". The present proposal will evaluate the ability of gabapentin maintenance to reduce the abuse liability of alcohol, oxycodone, and alcohol in combination with oxycodone in participants with both Opioid Use Disorder and Alcohol Use Disorder.
What is the current status of trial NCT03205423?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 17 participants. The study started on 2017-08-01. Estimated completion is 2021-12-30.
What interventions are being tested in trial NCT03205423?
The interventions under investigation include: Gabapentin (DRUG).
Who is sponsoring clinical trial NCT03205423?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.